We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Applied Biosystems Expands Line of TaqMan® MicroRNA Assays
Product News

Applied Biosystems Expands Line of TaqMan® MicroRNA Assays

Applied Biosystems Expands Line of TaqMan® MicroRNA Assays
Product News

Applied Biosystems Expands Line of TaqMan® MicroRNA Assays

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Applied Biosystems Expands Line of TaqMan® MicroRNA Assays"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

At the 2006 Annual Meeting of the American Association for Cancer Research, Applied Biosystems announced the commercial availability of 300 individual TaqMan® MicroRNA Assays (miRNA assays) for human, mouse, and rat studies.

MicroRNAs, one of the smallest entities in the human genome responsible for gene regulation, are a rapidly growing research area with implications for further understanding of gene regulation in normal development and in various disease states.

"Whether or not specific microRNAs are expressed in a cell often influences key cellular characteristics and functions carried out by that cell," said William V. Murray, Division President of Molecular Biology for Applied Biosystems.

"Scientists are quickly learning that these non-coding microRNA molecules play a critical regulatory role in cellular processes, such as differentiation and development, as well as in disease development, such as cancer. This is an exciting new field of study that we expect to grow as more microRNAs are discovered and functionally characterized."

The assays are based on a two-step process using Applied Biosystems' proprietary stem-loop technology for reverse transcription (RT) of the mature microRNA followed by quantitative real-time PCR.

In preliminary studies, the assays were able to quantify microRNAs in samples as small as 25 picograms of total RNA and discriminate between highly homologous mature microRNAs, such as the hsa-let-7 family.

"We have been using the TaqMan MicroRNA Assays to study types of brain tumors that respond differently to treatment," said Victor Ambros, Ph.D., Professor of Genetics, Dartmouth Medical School, who is also credited with the initial discovery of microRNA molecules.

"Our studies show these assays to be the most reliable and quantitative way to screen for microRNA biomarkers that distinguish tumor types."